Analysen von Matthew Weston
| 15.12.25 | Novo Nordisk Neutral | UBS AG | |
| 15.12.25 | Sanofi Buy | UBS AG | |
| 12.12.25 | Novo Nordisk Neutral | UBS AG | |
| 11.12.25 | Roche Buy | UBS AG | |
| 05.12.25 | Roche Buy | UBS AG | |
| 04.12.25 | GSK Neutral | UBS AG | |
| 04.12.25 | Novo Nordisk Neutral | UBS AG | |
| 02.12.25 | Bayer Neutral | UBS AG | |
|
Werbung
|
|||
| 01.12.25 | Novo Nordisk Neutral | UBS AG | |
| 25.11.25 | Bayer Neutral | UBS AG | |
| 21.11.25 | Novartis Neutral | UBS AG | |
| 20.11.25 | Novartis Neutral | UBS AG | |
| 19.11.25 | Roche Buy | UBS AG | |
| 18.11.25 | Novo Nordisk Neutral | UBS AG | |
| 14.11.25 | Merck Buy | UBS AG | |
| 13.11.25 | Merck Buy | UBS AG | |
| 11.11.25 | Novo Nordisk Neutral | UBS AG | |
| 10.11.25 | Novo Nordisk Neutral | UBS AG | |
| 10.11.25 | Roche Buy | UBS AG | |
| 07.11.25 | AstraZeneca Buy | UBS AG | |
| 06.11.25 | AstraZeneca Buy | UBS AG | |
| 06.11.25 | Novo Nordisk Neutral | UBS AG | |
| 05.11.25 | Novo Nordisk Neutral | UBS AG | |
| 04.11.25 | Novartis Neutral | UBS AG | |
| 31.10.25 | AstraZeneca Buy | UBS AG | |
| 30.10.25 | GSK Neutral | UBS AG | |
| 29.10.25 | Merck Buy | UBS AG | |
| 29.10.25 | Novartis Neutral | UBS AG | |
| 29.10.25 | GSK Neutral | UBS AG | |
| 27.10.25 | Sanofi Buy | UBS AG | |
| 24.10.25 | Sanofi Buy | UBS AG | |
| 24.10.25 | GSK Neutral | UBS AG | |
| 23.10.25 | Roche Buy | UBS AG | |
| 22.10.25 | GSK Neutral | UBS AG | |
| 22.10.25 | Novo Nordisk Neutral | UBS AG | |
| 20.10.25 | Merck Buy | UBS AG | |
| 17.10.25 | Merck Buy | UBS AG | |
| 13.10.25 | AstraZeneca Buy | UBS AG | |
| 13.10.25 | Roche Buy | UBS AG | |
| 13.10.25 | Novo Nordisk Neutral | UBS AG | |
| 13.10.25 | Novartis Neutral | UBS AG | |
| 10.10.25 | Novartis Neutral | UBS AG | |
| 10.10.25 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 10.10.25 | Sartorius vz. Neutral | UBS AG | |
| 06.10.25 | Novo Nordisk Neutral | UBS AG | |
| 03.10.25 | Novo Nordisk Neutral | UBS AG | |
| 03.10.25 | Sanofi Buy | UBS AG | |
| 24.09.25 | Novartis Neutral | UBS AG | |
| 23.09.25 | Roche Buy | UBS AG | |
| 23.09.25 | Novartis Neutral | UBS AG | |